Evidence Explorer · MS-N233 · Traditional Persian herbal preparation · Supportive care · Appraised November 4, 2026
A four-week open-label randomized study favored an Alcea digitata–Malva sylvestris infusion over artificial saliva for selected dry-mouth and quality-of-life scores. The magnitude and durability remain uncertain.
Evidence at a glance
Benefit signal: Possible short-term xerostomia symptom benefit
Certainty: Very low; small open-label active-control trial with subjective outcomes
Risk context: Mild nausea, gastric discomfort and polyuria; manufacturing and interaction data are limited
What was studied
Sixty-two people with head-and-neck cancer and radiation-related xerostomia were assigned to the herbal preparation or Hypozalix artificial saliva for four weeks. The exact research dose was not verified from the accessible abstract.
EORTC QLQ-H&N35 total and dry-mouth scores favored the herbal group at four weeks (P=.007 and P=.017). Visual-analog dry-mouth findings also favored the preparation in a related report.
What this evidence cannot establish
Participants knew which treatment they received, and effect sizes, confidence intervals, adherence and longer follow-up were incompletely reported. Improvement over one artificial-saliva product does not establish superiority over comprehensive xerostomia care.
The trial evaluated symptoms after radiotherapy; it did not test tumor response or survival.
Practical safety context
Mild nausea, gastric discomfort and polyuria were reported. Mucilage-rich herbs may alter absorption of oral medicines if taken together; spacing and pharmacist review are prudent.
Persistent dry mouth raises dental-caries, infection and swallowing risks. Fluoride, dental follow-up, hydration and salivary evaluation remain important.
Questions for the care team
- What exact species, preparation and dose were studied?
- Should the infusion be separated from oral cancer medicines or thyroid medication?
- What dental and fluoride plan is in place?
- Would saliva substitutes, stimulants or specialist evaluation be more appropriate?
Funding and conflicts
Detailed funding and conflicts were not verified from the accessible abstract. The 2026 review rated the evidence very low certainty.
Sources
- Randomized active-controlled trial (PMID 28494850)
- 2026 systematic review of oral herbal preparations in supportive cancer care (PMID 42930516)
Sources and publication status checked November 4, 2026. Last literature search: November 4, 2026; record appraisal: November 4, 2026.
For education, not personal medical advice. Research regimens are not personal prescriptions. Symptom, laboratory or biomarker changes do not establish tumor response, recurrence prevention or longer survival.
